Meta Information
ID:potassium-chloride
Name:Potassium Chloride
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-07-02T06:42:50Z
Model
phase-b-newfiles-claude-opus-4.8
Interactions
Target id:
/class/potassium-sparing-diuretics
Target name:
Potassium-sparing diuretics (spironolactone, triamterene, amiloride)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Potassium-sparing diuretics block potassium excretion; adding potassium can cause severe, dangerous hyperkalemia.
Actionable advice:
Potassium supplements should not be taken with potassium-sparing diuretics unless specifically directed and monitored.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene, or amiloride) since the simultaneous administration of these agents can produce severe hyperkalemia.
Label source:
fda_label
Action type:
avoid
Target id:
/class/ace-inhibitors
Target name:
ACE inhibitors
Severity:
major
Interaction type:
adverse
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
ACE inhibitors reduce aldosterone and cause potassium retention; adding potassium raises the risk of hyperkalemia.
Actionable advice:
Serum potassium should be monitored closely, and supplemental potassium is often unnecessary and can be harmful with an ACE inhibitor.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy.
Label source:
fda_label
Action type:
monitor
Target id:
/class/arbs
Target name:
Angiotensin receptor blockers (ARBs)
Severity:
major
Interaction type:
adverse
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
ARBs cause potassium retention; combined with supplemental potassium this raises hyperkalemia risk.
Actionable advice:
Serum potassium should be monitored closely, and extra potassium is usually not needed with an ARB.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy.
Label source:
fda_label
Action type:
monitor
Target id:
/class/nsaids
Target name:
NSAIDs
Severity:
moderate
Interaction type:
adverse
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
NSAIDs reduce potassium excretion by the kidney, adding to hyperkalemia risk with potassium supplements.
Actionable advice:
Serum potassium should be monitored if NSAIDs are used regularly with potassium.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
Nonsteroidal anti-inflammatory drugs (NSAIDs) may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients receiving concomitant NSAID therapy.
Label source:
fda_label
Action type:
monitor
Target id:
/class/anticholinergic-medications
Target name:
Anticholinergic drugs (delayed GI transit)
Severity:
major
Interaction type:
adverse
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Anticholinergics slow the gut; solid potassium tablets can then sit against the gut lining and cause ulcers or narrowing.
Actionable advice:
Solid oral potassium should be avoided with anticholinergics that delay GI transit; a liquid/effervescent form is preferable if potassium is needed.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
All solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological... or pharmacologic (use of anticholinergic agents...) cause for arrest or delay in tablet passage through the gastrointestinal tract.
Label source:
fda_label
Action type:
avoid
Target id:
/condition/renal-impairment
Target name:
Severe renal impairment / hyperkalemia
Severity:
major
Interaction type:
contraindication
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Impaired kidneys cannot excrete potassium, so supplements can cause dangerous hyperkalemia and cardiac arrest.
Actionable advice:
Potassium supplements should not be taken in significant kidney impairment or hyperkalemia without specialist supervision.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
Potassium supplements are contraindicated in patients with hyperkalemia.
Label source:
fda_label
Action type:
avoid
Target id:
/class/potassium-elevators
Target name:
Trimethoprim, heparin (other potassium-raising drugs)
Severity:
moderate
Interaction type:
adverse
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Trimethoprim (blocks renal potassium excretion) and heparin (suppresses aldosterone) can add to hyperkalemia risk with potassium.
Actionable advice:
Serum potassium should be monitored when combining. FLAG: these two are not named in the FDA potassium label - mechanism is well-established (Lexicomp-level).
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Trimethoprim has amiloride-like ENaC blockade and heparin suppresses aldosterone; both reduce potassium excretion. Well-established pharmacology; not in the FDA KCl label.
Label source:
Class inference
Action type:
monitor